Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine

被引:10
|
作者
Chowdhury, Fahima [1 ]
Bhuiyan, Taufiqur Rahman [1 ]
Akter, Afroza [1 ]
Bhuiyan, Md Saruar [1 ]
Khan, Ashraful Islam [1 ]
Tauheed, Imam [1 ]
Ahmed, Tasnuva [1 ]
Ferdous, Jannatul [1 ]
Dash, Pinki [1 ]
Basher, Salima Raiyan [1 ]
Al Hakim [1 ]
Lynch, Julia [2 ]
Kim, Jerome H. [2 ]
Excler, Jean-Louis [2 ]
Kim, Deok Ryun [2 ]
Clemens, John D. [1 ,3 ,4 ]
Qadri, Firdausi [1 ]
机构
[1] Int Ctr Diarrhoeal Dis Res, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh
[2] Int Vaccine Inst, Seoul, South Korea
[3] UCLA, Fielding Sch Publ Hlth, Los Angeles, CA USA
[4] Korea Univ, Sch Med, Seoul, South Korea
基金
比尔及梅琳达.盖茨基金会;
关键词
Oral Cholera Vaccine (OCV); Augmented immune response; Booster dose; Primary dose; Shanchol; ANTIBODY-SECRETING CELL; SUBUNIT-WHOLE-CELL; VIBRIOCIDAL ANTIBODY; DOUBLE-BLIND; B-CELLS; IMMUNOGENICITY; ANTIGEN; SAFETY; PROTECTION; INFECTION;
D O I
10.1016/j.vaccine.2019.12.034
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have earlier reported that a single dose of oral cholera vaccine (OCV) is protective in adults and children >= 5 years of age and sustained for 2 years. We enrolled participants (n = 240) from this study, between March-September 2017, over 3 years after receiving a primary single dose. Immune responses were measured in placebo group (Primary Immunization group: PI) and compared with those who received a single dose (Booster Immunization group: BI). The children were 4 to <5 years, 5 to <18 years and adults >18 years. Blood was collected at day 0 (before vaccination) and after receiving 1st and 2nd doses of OCV. Overall, the BI and PI groups showed vibriocidal antibody response after 1st and 2nd dose of vaccination in all age groups to V. cholerae O1 and O139. Young children in the BI group showed significantly higher vibriocidal antibody response two weeks after receiving the first dose as compared to PI group to LPS. Elevated plasma IgA responses to LPS after the first dose were observed among the BI group compared to the PI group among the young children. Mucosal antibody responses measured in fecal extracts showed similar increases as that of vibriocidal and LPS responses in the BI group. These results suggest a single boosting dose of OCV generated immune response in primed population >5 years of age who had earlier received OCV. However, young children who had received OCV earlier, boosting after a single dose, resulted in increased immune responses compared to the PI group. Further studies are needed to assess protection obtained from different strategies, especially for young children and to determine the numbers of primary and booster doses needed. In addition, more information is needed regarding the optimum interval between primary and booster doses to plan future interventions for cholera control. (C) 2019 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:1753 / 1761
页数:9
相关论文
共 22 条
  • [1] Requirement of a Booster Dose of Hepatitis B Vaccine in Children With Thalassemia After 5 Years of Primary Vaccination: A Prospective Study
    Gomber, Sunil
    Yadav, Ravinder
    Dewan, Pooja
    Ramachandran, V. G.
    Puri, A. S.
    INDIAN PEDIATRICS, 2021, 58 (03) : 237 - 240
  • [2] Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years
    Zhang, Yukai
    Wang, Lei
    Wang, Yanxia
    Zhang, Wei
    Jia, Ningning
    Xie, Zhiqiang
    Huang, Lili
    You, Wangyang
    Lu, Weifeng
    Li, Erwei
    Gao, Feilong
    Hu, Yuansheng
    Meng, Fanhong
    Xia, Shengli
    VACCINES, 2022, 10 (05)
  • [3] Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age
    Robertson, Corwin A.
    Jacqmein, Jeffry
    Selmani, Alexandre
    Galarza, Katherine
    Oster, Philipp
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [4] Immune persistence 17 to 20years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination
    Zhao, Yu-Liang
    Han, Bi-Hua
    Zhang, Xin-Jiang
    Pan, Lu-Lu
    Zhou, Hai-Song
    Gao, Zhao
    Hao, Zhi-Yong
    Wu, Zhi-Wei
    Ma, Tian-Li
    Wang, Feng
    Li, Qi
    Bi, Sheng-Li
    Ma, Jing-Chen
    BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [5] Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination
    Block, Stan L.
    Christensen, Shane
    Verma, Bikash
    Xie, Fang
    Keshavan, Pavitra
    Dull, Peter M.
    Smolenov, Igor
    VACCINE, 2015, 33 (18) : 2175 - 2182
  • [6] Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age
    Bijukchhe, Sanjeev M.
    Gurung, Meeru
    Pokhrel, Bhishma
    Shakya, Mila
    Pant, Dikshya
    Maskey, Pratistha
    Maskey, Himang
    Dhakal, Babita
    Rajkarkinar, Shristy
    Bista, Sabitri
    Voysey, Merryn
    Mujadidi, Yama F.
    Kim, Young Chan
    Atherton, Rachel
    Jones, Elizabeth
    Mclean, Florence
    Shrestha, Sonu
    Hill, Matilda
    Nyland, Katherine Theiss
    Kelly, Sarah
    'reilly, Peter
    Sah, Ganesh Prasad
    Basnyat, Buddha
    Pollard, Andrew J.
    Shrestha, Shrijana
    VACCINE, 2024, 42 (08) : 2018 - 2025
  • [7] Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose
    Kadlecek, Vera
    Borja-Tabora, Charissa Fay
    Eder-Lingelbach, Susanne
    Gatchalian, Salvacion
    Kiermayr, Sigrid
    Sablan, Benjamin, Jr.
    Kundi, Michael
    Taucher, Christian
    Dubischar, Katrin L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (09) : E233 - E240
  • [8] Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization
    Kosalaraksa, Pope
    Watanaveeradej, Veerachai
    Pancharoen, Chitsanu
    Rosario Capeding, Maria
    Feroldi, Emmanuel
    Bouckenooghe, Alain
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (04) : E108 - E113
  • [9] Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America Evaluation 4-5 Years After a Primary 3-Dose Schedule
    Coronel, Diana
    Garcia-Rivera, Enid J.
    Rivera, Maribel
    Luis Arredondo-Garcia, Jose
    Dietze, Reynaldo
    Perroud, Ana Paula
    Cortes, Margarita
    Bonaparte, Matthew
    Zhao, Jessie
    Tila, Mihaela
    Jackson, Nick
    Zambrano, Betzana
    Noriega, Fernando
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (05) : E90 - E95
  • [10] Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine
    Knuf, Markus
    Helm, Klaus
    Kolhe, Devayani
    Van Der Wielen, Marie
    Baine, Yaela
    VACCINE, 2018, 36 (23) : 3286 - 3295